GCKR and diabetes mellitus: Two optimized molecules, AMG‐1694 and AMG‐3969, were advanced into preclinical models of diabetes and demonstrated efficacy in all tested diabetic models by reversing the inhibitory effect of GCKR on GCK activity and promoting GCK translocation [32].